{
  "nctId": "NCT03531710",
  "briefTitle": "An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311",
  "officialTitle": "An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)",
  "protocolDocument": {
    "nctId": "NCT03531710",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-01-22",
    "uploadDate": "2020-06-01T14:20",
    "size": 1057884,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03531710/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 34,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-08-10",
    "completionDate": "2019-10-31",
    "primaryCompletionDate": "2019-10-31",
    "firstSubmitDate": "2018-04-06",
    "firstPostDate": "2018-05-22"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients who participated in V203-AD trial without major safety concerns;\n* Stable doses of permitted medications for 3 months before screening;\n* With a caregiver;\n* Other inclusion criteria apply\n\nExclusion Criteria:\n\n* Clinically significant neurological disease other than Alzheimer's disease\n* Major psychiatric disorder\n* Severe systemic disease\n* Serious adverse reactions to any vaccine\n* Other exclusion criteria apply",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "60 Years",
    "maximumAge": "90 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "The Incidence of Adverse Event (AE)/Serious Adverse Event (SAE) [Safety and Tolerability]).",
        "description": "Summary of Treatment Emergent Adverse Events (TEAEs), based on reported adverse events and other safety information including local tolerability at injection site, MRI, vital signs, physical examination, 12-lead ECG and laboratory tests.",
        "timeFrame": "Overall Study Duration/Early Termination, over an average study duration of 326 days"
      },
      {
        "measure": "Change From Baseline and Through to the End of the Study in Anti-Aβ Antibody Titers [The Immunogenicity of UB-311]",
        "description": "For the immunogenicity assessment of the investigational product, UB-311, the level of anti-Aβ antibodies in the serum samples will be measured by a validated enzyme immunoassay manufactured by United Biomedical, Inc. (UBI). The level of anti-Aβ antibodies is assessed at every visit throughout the study period.",
        "timeFrame": "Overall Study Duration/Early Termination, over an average study duration of 326 days"
      }
    ],
    "secondary": [],
    "other": [
      {
        "measure": "Change From Baseline and Through to the End of the Study in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog);",
        "description": "The ADAS-Cog 13 contains 13 items, with a total scoring range of 0 - 85 and higher scores indicating greater dysfunction. ADAS-Cog scores were evaluated at V1 and V8/ET. The observed values and change from baseline for ADAS-Cog scores by treatment groups in the extension study are presented",
        "timeFrame": "Overall Study Duration/Early Termination, over an average study duration of 326 days"
      },
      {
        "measure": "Change From Baseline and Through to the End of the Study in Mini-Mental State Exam (MMSE)",
        "description": "The MMSE is a 30-point questionnaire. The total score range is 0 - 30 and lower scores indicating greater impairment. MMSE scores were evaluated at V1 and V8/ET. The observed values and change from baseline for MMSE scores by treatment groups in the extension study are presented",
        "timeFrame": "Overall Study Duration/Early Termination, over an average study duration of 326 days"
      },
      {
        "measure": "Change From Baseline and Through to the End of the Study in Clinical Dementia Rating - Sum of Boxes (CDR-SB)",
        "description": "The CDR-SB includes 6 domains (0 - 3 points/domain), with a total scoring range of 0 - 18 and higher scores indicate greater impartment. CDR-SB scores were evaluated at V1 and V8/ET. The observed values and change from baseline for CDR-SB scores by treatment groups in the extension study are presented",
        "timeFrame": "Overall Study Duration/Early Termination, over an average study duration of 326 days"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 0,
      "otherCount": 3,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 45,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:41.297Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}